Accelerating Alzheimer’s therapeutic development: The past and future of clinical trials

• Published in: Cell 2023-10, Vol.186 (22), p.4757-4772
• Main Authors: Boxer, Adam L., Sperling, Reisa
• Format: Article
• Language: English
• Subjects: Alzheimer Disease - diagnosis; Alzheimer Disease - drug therapy; Alzheimer Disease - pathology; Amyloid beta-Peptides; Amyloidogenic Proteins; Antibodies, Monoclonal - therapeutic use; Biomarkers; Clinical Trials as Topic; Drug Development; Humans
• ISSN: 0092-8674; 1097-4172; 1097-4172
• DOI: 10.1016/j.cell.2023.09.023

Alzheimer’s disease (AD) research has entered a new era with the recent positive phase 3 clinical trials of the anti-Aβ antibodies lecanemab and donanemab. Why did it take 30 years to achieve these successes? Developing potent therapies for reducing fibrillar amyloid was key, as was selection of patients at relatively early stages of disease. Biomarkers of the target pathologies, including amyloid and tau PET, and insights from past trials were also critical to the recent successes. Moving forward, the challenge will be to develop more efficacious therapies with greater efficiency. Novel trial designs, including combination therapies and umbrella and basket protocols, will accelerate clinical development. Better diversity and inclusivity of trial participants are needed, and blood-based biomarkers may help to improve access for medically underserved groups. Incentivizing innovation in both academia and industry through public-private partnerships, collaborative mechanisms, and the creation of new career paths will be critical to build momentum in these exciting times.